beta-alanine has been researched along with Thromboembolism, Venous in 134 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two independent investigators reviewed bleeding reports from 1034 individuals with 1121 major bleeds enrolled in 5 phase III trials comparing dabigatran with warfarin in 27 419 patients treated for 6 to 36 months." | 10.27 | Management and outcomes of major bleeding during treatment with dabigatran or warfarin. ( Brueckmann, M; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Hwang, HG; Majeed, A; Schulman, S; Wallentin, L; Yusuf, S, 2013) |
| "Dabigatran has similar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the treatment of acute VTE." | 9.19 | Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. ( Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S, 2014) |
| "Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism." | 9.17 | Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. ( Baanstra, D; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Kvamme, AM; Mismetti, P; Schellong, S; Schulman, S, 2013) |
| "Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation." | 8.90 | Increased risk of myocardial infarction with dabigatran: fact or fiction? ( Basile, E; Di Biase, L; Giglio, AF; Natale, A; Santangeli, P; Trotta, F, 2014) |
| "The first study on the treatment of venous thromboembolism (VTE) with dabigatran (RE-COVER) was published in 2009." | 8.88 | Treatment of venous thromboembolism with dabigatran. ( Schulman, S, 2012) |
| "Vitamin-K antagonists have played a dominant role in the long-term management of patients with venous thromboembolism, and large trials from the past decade reinforced warfarin's effectiveness as an intermediate-duration and extended-duration anticoagulant." | 8.87 | Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial. ( Deloughery, TG; Liem, TK, 2011) |
| "According to this study, the introduction of apixaban may reduce the rate of VTE and bleeding compared with enoxaparin, decreasing the expenditure of NHS in VTE prophylaxis." | 7.78 | [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. ( Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C, 2012) |
| "To compare the efficacy, in the prevention of venous thromboembolism (VTE), and safety, of rivaroxaban and dabigatran relative to the common comparator enoxaparin." | 7.77 | An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. ( Diamantopoulos, A; Lees, M; Lereun, C; Rasul, F; Sengupta, N; Wells, P, 2011) |
| " Additional concerns refer to the dosing-regimens and their practical administration: Fondaparinux, rivaroxaban and dabigatran are dosed to achieve maximum effects very close to their limits of tolerance whereas wide dosing spectra for the low molecular weight herparin (LMWH)'s indicate the potential for dose adaptation and increase." | 6.47 | Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux. ( Fareed, J; Hull, R; Welzel, D, 2011) |
| "Dabigatran etexilate is a novel orally administered anticoagulant that exerts its action through reversible direct thrombin inhibition." | 6.47 | A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery. ( Majeed, A; Schulman, S, 2011) |
| "Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 6.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
| "Two independent investigators reviewed bleeding reports from 1034 individuals with 1121 major bleeds enrolled in 5 phase III trials comparing dabigatran with warfarin in 27 419 patients treated for 6 to 36 months." | 6.27 | Management and outcomes of major bleeding during treatment with dabigatran or warfarin. ( Brueckmann, M; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Hwang, HG; Majeed, A; Schulman, S; Wallentin, L; Yusuf, S, 2013) |
| "Dabigatran has similar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the treatment of acute VTE." | 5.19 | Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. ( Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S, 2014) |
| "Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism." | 5.17 | Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. ( Baanstra, D; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Kvamme, AM; Mismetti, P; Schellong, S; Schulman, S, 2013) |
| "In patients undergoing hip or knee arthroplasty, enoxaparin and dabigatran showed similar rates of efficacy and bleeding." | 5.14 | Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. ( Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S, 2010) |
| "Novel oral anticoagulants (NOACs) including apixaban, dabigatran and rivaroxaban have been approved by international regulatory agencies to prevent venous thromboembolism as well as treat atrial fibrillation and venous thromboembolism in individuals with chronic kidney disease (CKD)." | 4.91 | Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease. ( Harel, Z; Perl, J; Sood, MM, 2015) |
| " They are effective and safe compared to warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation and for the treatment of venous thromboembolism, and they are comparable to low-molecular-weight heparin for thromboprophylaxis after hip or knee arthroplasty." | 4.91 | Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? ( Arepally, GM; Ortel, TL, 2015) |
| "The objective of this analysis was to test the equivalence of three NOACs (dabigatran, rivaroxaban, apixaban) in orthopedic surgery and four NOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) in non-valvular atrial fibrillation." | 4.91 | Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation. ( Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S, 2015) |
| "During the past four years the phase III trials on stroke prophylaxis in atrial fibrillation and on treatment of venous thromboembolism have been completed for four new oral anticoagulants - dabigatran, apixaban, edoxaban and rivaroxaban." | 4.90 | New oral anticoagulant agents - general features and outcomes in subsets of patients. ( Schulman, S, 2014) |
| "Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation." | 4.90 | Increased risk of myocardial infarction with dabigatran: fact or fiction? ( Basile, E; Di Biase, L; Giglio, AF; Natale, A; Santangeli, P; Trotta, F, 2014) |
| "The new oral anticoagulants (NOACs), which include dabigatran, rivaroxaban, apixaban, and edoxaban, are poised to replace warfarin for treatment of the majority of patients with venous thromboembolism (VTE)." | 4.90 | Evolving use of new oral anticoagulants for treatment of venous thromboembolism. ( Gross, PL; Weitz, JI; Yeh, CH, 2014) |
| "Rivaroxaban is the first TSOAC to gain widespread approval for the treatment of acute deep vein thrombosis and pulmonary embolism and the long-term prevention of recurrent VTE as monotherapy." | 4.90 | The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism. ( Akwaa, F; Spyropoulos, AC, 2014) |
| " Dabigatran, rivaroxaban, apixaban, and edoxaban have been shown to be as effective as warfarin in the treatment and prevention of venous thromboembolism and prevention of stroke in nonvalvular atrial fibrillation." | 4.90 | Target-specific oral anticoagulants: practice issues for the clinician. ( Giugliano, RP; Plitt, A, 2014) |
| "All NOACs are at least as effective as warfarin for stroke prevention in patients with nonvalvular AF, and are at least as safe in terms of bleeding risk according to 3 large trials." | 4.90 | Approach to the new oral anticoagulants in family practice: part 1: comparing the options. ( Bell, AD; Douketis, J; Eikelboom, J; Liew, A, 2014) |
| "The new oral agents demonstrate several advantages over traditional anticoagulants, including administration at fixed doses and no requirement for routine coagulation monitoring On the basis of phase III clinical trials, rivaroxaban, apixaban and dabigatran etexilate have been approved in many countries for the prevention of venous thromboembolism after hip and knee replacement surgery." | 4.89 | Implications of new anticoagulants in primary practice. ( Eraso, LH; Merli, GJ; Perez, A, 2013) |
| " We review new anticoagulants that have been introduced recently to the market or that are undergoing investigations for treatment of nonvalvular atrial fibrillation and venous thromboembolism prophylaxis: Dabigatran, rivaroxaban, apixiban, and edoxaban." | 4.89 | The novel anticoagulants: the surgeons' prospective. ( Martin, EN; Money, SR; Shamoun, FE, 2013) |
| " The US Food and Drug Administration recently approved 2 new oral anticoagulants, dabigatran and rivaroxaban, for stroke prevention in patients with atrial fibrillation, and is currently reviewing a drug application for a third new oral anticoagulant, apixaban." | 4.89 | Novel oral anticoagulants: a review of new agents. ( Wanat, MA, 2013) |
| "The direct thrombin inhibitor, dabigatran, and the selective factor Xa inhibitors, rivaroxaban and apixaban, are new oral anticoagulants that are approved in many countries for prevention of venous thromboembolism in patients undergoing elective hip or knee arthroplasty." | 4.89 | Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery. ( Eriksson, BI; Quinlan, DJ, 2013) |
| "To summarise and compare the efficacy and safety of various oral anticoagulants (dabigatran, rivaroxaban, apixaban, and vitamin K antagonists) and antiplatelet agents (acetylsalicylic acid) for the secondary prevention of venous thromboembolism." | 4.89 | Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. ( Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS, 2013) |
| "Indications for use of the new anticoagulants include thromboprophylaxis after total hip and knee replacement surgery (all three), prevention of stroke and systemic embolism in non-valvular atrial fibrillation (all three), treatment of acute venous thrombosis and secondary prophylaxis after venous thrombosis (currently only rivaroxaban)." | 4.89 | New oral anticoagulants--a review. ( Atar, D; Ghanima, W; Sandset, PM, 2013) |
| "The first study on the treatment of venous thromboembolism (VTE) with dabigatran (RE-COVER) was published in 2009." | 4.88 | Treatment of venous thromboembolism with dabigatran. ( Schulman, S, 2012) |
| "Prospective, double-blind studies in orthopaedic patients have been conducted using the direct thrombin inhibitor dabigatran etexilate (hereafter referred to as dabigatran), with two doses investigated and approved for adults (220 mg and 150 mg once daily) to prevent venous thromboembolism (VTE)." | 4.88 | Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]. ( Clemens, A; Dahl, OE; Eriksson, BI; Kurth, AA; Noack, H; Rosencher, N, 2012) |
| "The present systematic review was conducted to assess the efficacy and safety of apixaban versus other anticoagulants, for the prevention of venous thromboembolism (VTE) following total hip replacement (THR) and total knee replacement (TKR) surgery." | 4.88 | The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis. ( Cohen, A; Drost, P; Marchant, N; Mitchell, S; Orme, M; Rublee, D; Simon, TA; Sutton, A, 2012) |
| " Compared with enoxaparin, the risk of symptomatic venous thromboembolism was lower with rivaroxaban (relative risk 0." | 4.88 | Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. ( Gómez-Outes, A; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E, 2012) |
| "Vitamin-K antagonists have played a dominant role in the long-term management of patients with venous thromboembolism, and large trials from the past decade reinforced warfarin's effectiveness as an intermediate-duration and extended-duration anticoagulant." | 4.87 | Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial. ( Deloughery, TG; Liem, TK, 2011) |
| "Dabigatran, a direct thrombin inhibitor, is licensed for the prevention of venous thromboembolism after knee and hip replacement, the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of acute venous thromboembolism." | 3.80 | Dabigatran: patient management in specific clinical settings. ( Binder, K; Domanovits, H; Eichinger, S; Függer, R; Gollackner, B; Hiesmayr, JM; Huber, K; Kyrle, PA; Lang, W; Perger, P; Quehenberger, P; Roithinger, FX; Schmaldienst, S; Weltermann, A, 2014) |
| "This study evaluated differences in medical costs associated with clinical end-points from randomized clinical trials that compared the new oral anticoagulants (NOACs), dabigatran, rivaroxaban, apixaban, and edoxaban, to standard therapy for treatment of patients with venous thromboembolism (VTE)." | 3.80 | Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients. ( Amin, A; Graham, J; Jing, Y; Lin, J; Lingohr-Smith, M; Trocio, J, 2014) |
| " Based on the results of the studies, dabigatran, rivaroxaban and apixaban have been approved by the European Medicines Agency for the prevention of venous thromboembolism after elective hip or knee replacement surgery." | 3.79 | Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients. ( Ageno, W; Bozzato, S; Donadini, MP; Riva, N, 2013) |
| "Three pivotal phase 3 trials have demonstrated that oral dabigatran etexilate showed similar safety and efficacy to enoxaparin 40 mg once daily (qd) for venous thromboembolism (VTE) prevention in patients undergoing total knee or hip replacement." | 3.78 | Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. ( Clemens, A; Dahl, OE; Eriksson, BI; Feuring, M; Friedman, RJ; Hantel, S; Huo, M; Noack, H, 2012) |
| "According to this study, the introduction of apixaban may reduce the rate of VTE and bleeding compared with enoxaparin, decreasing the expenditure of NHS in VTE prophylaxis." | 3.78 | [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. ( Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C, 2012) |
| "To compare the efficacy, in the prevention of venous thromboembolism (VTE), and safety, of rivaroxaban and dabigatran relative to the common comparator enoxaparin." | 3.77 | An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. ( Diamantopoulos, A; Lees, M; Lereun, C; Rasul, F; Sengupta, N; Wells, P, 2011) |
| "These trials enrolled 5167 people with cancer and VTE." | 2.58 | Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. ( Akl, EA; Barba, M; Hakoum, MB; Kahale, LA; Matar, CF; Schünemann, H; Sperati, F; Terrenato, I; Tsolakian, IG; Yosuico, VE, 2018) |
| "Dabigatran is a direct thrombin (factor IIa) inhibitor; rivaroxaban and apixaban are direct factor Xa inhibitors." | 2.50 | Newer clinically available antithrombotics and their antidotes. ( Lévy, S, 2014) |
| "Warfarin and heparins have been the predominant anticoagulants used until the past decade." | 2.50 | The newer direct oral anticoagulants: a practical guide. ( Thachil, J, 2014) |
| " They are at least as effective and as safe as conventional therapy (heparins and vitamin-K inhibitors) and have practical advantages, such as fixed dosing and no need for laboratory monitoring." | 2.50 | Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. ( Bounameaux, H; Fontana, P; Goldhaber, SZ, 2014) |
| "The decision for a patient with cancer and VTE to start long-term LMWH versus oral anticoagulation should balance the benefits and harms and integrate the patient's values and preferences for the important outcomes and alternative management strategies." | 2.50 | Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. ( Akl, EA; Barba, M; Kahale, L; Labedi, N; Muti, P; Neumann, I; Schünemann, H; Sperati, F; Terrenato, I, 2014) |
| "Venous thromboembolism is a common cause of morbidity and mortality among patients undergoing elective orthopedic surgery." | 2.49 | The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. ( Aldin, ES; Greenberg, C; Rachidi, S; Sachs, B; Streiff, M; Zeidan, AM, 2013) |
| "Risk for symptomatic deep venous thrombosis, but not risk for death or nonfatal pulmonary embolism, was reduced with factor Xa inhibitors compared with LMWH (4 fewer events per 1000 patients)." | 2.49 | Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. ( Adam, SS; Lachiewicz, PF; McDuffie, JR; Ortel, TL; Williams, JW, 2013) |
| "Venous thromboembolism is associated with significant mortality and morbidity, with patients being at risk of recurrence, post-thrombotic syndrome, and chronic thromboembolic pulmonary hypertension." | 2.48 | New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders. ( Dahl, OE, 2012) |
| "Warfarin has been the only available oral anticoagulant therapy for several decades." | 2.48 | Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome. ( Khemasuwan, D; Suramaethakul, N, 2012) |
| "Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 2.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
| "Dabigatran etexilate is a novel orally administered anticoagulant that exerts its action through reversible direct thrombin inhibition." | 2.47 | A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery. ( Majeed, A; Schulman, S, 2011) |
| " Additional concerns refer to the dosing-regimens and their practical administration: Fondaparinux, rivaroxaban and dabigatran are dosed to achieve maximum effects very close to their limits of tolerance whereas wide dosing spectra for the low molecular weight herparin (LMWH)'s indicate the potential for dose adaptation and increase." | 2.47 | Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux. ( Fareed, J; Hull, R; Welzel, D, 2011) |
| "Dabigatran is a direct thrombin (FIIa) inhibitor, whereas Rivaroxaban and Apixaban are direct factor Xa (FXa) inhibitors." | 2.47 | [The new Anticoagulants - Relevant Facts for the GP]. ( Asmis, LM, 2011) |
| "Dabigatran is an oral direct thrombin inhibitor with a rapid onset." | 2.47 | Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor. ( Augoustides, JG, 2011) |
| "Dabigatran is a direct thrombin inhibitor that has undergone clinical trials for VTE prophylaxis and treatment." | 2.46 | New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors. ( Morris, TA, 2010) |
| " The RapidTEG activated clotting time test allowed the creation of a dose-response curve for all 3 NOACs." | 1.42 | Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants. ( Dias, JD; Doorneweerd, DD; Norem, K; Omert, LA; Popovsky, MA; Thurer, RL, 2015) |
| " As with warfarin, patients taking NOACs should avoid long-term use of nonsteroidal anti-inflammatory and antiplatelet drugs." | 1.40 | Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. ( Bell, AD; Douketis, J; Eikelboom, J; Liew, A, 2014) |
| " These drugs differ in a several important respects from warfarin; most notably they have a reliable dose-response effect which means they can be given without the need for monitoring." | 1.39 | New oral anticoagulants: their role and future. ( Laffan, M; Shapiro, S, 2013) |
| "Rivaroxaban is a direct inhibitor of activated factor X, and dabigatran is a direct inhibitor of thrombin." | 1.39 | [New oral anticoagulants in the treatment of venous thromboembolic disease]. ( Calvo Romero, JM; Lima Rodríguez, EM, 2013) |
| "Based on these results, prevention and treatment of venous thromboembolism will change substantially in the near future." | 1.37 | [New anticoagulants in the prevention and treatment of venous thromboembolism]. ( Keltai, K; Keltai, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 134 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kahale, LA | 1 |
| Hakoum, MB | 1 |
| Tsolakian, IG | 1 |
| Matar, CF | 1 |
| Terrenato, I | 2 |
| Sperati, F | 2 |
| Barba, M | 2 |
| Yosuico, VE | 1 |
| Schünemann, H | 2 |
| Akl, EA | 2 |
| Connors, JM | 1 |
| Schulman, S | 9 |
| Kearon, C | 2 |
| Kakkar, AK | 2 |
| Schellong, S | 2 |
| Eriksson, H | 2 |
| Baanstra, D | 1 |
| Kvamme, AM | 1 |
| Friedman, J | 2 |
| Mismetti, P | 2 |
| Goldhaber, SZ | 3 |
| Riva, N | 1 |
| Donadini, MP | 1 |
| Bozzato, S | 1 |
| Ageno, W | 3 |
| Guijarro Merino, R | 1 |
| Villalobos Sánchez, A | 1 |
| Marchena Yglesias, PJ | 1 |
| Llau, JV | 1 |
| Ferrandis, R | 1 |
| Castillo, J | 1 |
| de Andrés, J | 1 |
| Gomar, C | 1 |
| Gómez-Luque, A | 1 |
| Hidalgo, F | 1 |
| Torres, LM | 1 |
| Piñero-Saavedra, M | 1 |
| Castaño, MP | 1 |
| Camarero, MO | 1 |
| Milla, SL | 1 |
| Kwok, CS | 2 |
| Pradhan, S | 1 |
| Yeong, JK | 1 |
| Loke, YK | 2 |
| Calvo Romero, JM | 1 |
| Lima Rodríguez, EM | 1 |
| Jacobson, BF | 1 |
| Louw, S | 1 |
| Büller, H | 1 |
| Mer, M | 1 |
| de Jong, PR | 1 |
| Rowji, P | 1 |
| Schapkaitz, E | 1 |
| Adler, D | 1 |
| Beeton, A | 1 |
| Hsu, HC | 1 |
| Wessels, P | 1 |
| Haas, S | 2 |
| Spyropoulos, AC | 3 |
| Turpie, AG | 2 |
| Gallego, P | 1 |
| Roldan, V | 1 |
| Lip, GY | 2 |
| Einecke, D | 1 |
| Liem, TK | 2 |
| DeLoughery, TG | 2 |
| Franck, AJ | 1 |
| Bovio, JA | 1 |
| Hegerfeldt, Y | 1 |
| Edwards, JL | 1 |
| El-Daly, I | 1 |
| Reidy, J | 1 |
| Culpan, P | 1 |
| Bates, P | 1 |
| Páramo, JA | 1 |
| Wanat, MA | 1 |
| den Exter, PL | 2 |
| Kooiman, J | 2 |
| van der Hulle, T | 2 |
| Huisman, MV | 3 |
| Agnelli, G | 1 |
| Becattini, C | 1 |
| Franco, L | 1 |
| Quinlan, DJ | 2 |
| Eriksson, BI | 4 |
| Cohen, AA | 1 |
| Rider, T | 1 |
| Castellucci, LA | 1 |
| Cameron, C | 1 |
| Le Gal, G | 1 |
| Rodger, MA | 1 |
| Coyle, D | 1 |
| Wells, PS | 1 |
| Clifford, T | 1 |
| Gandara, E | 1 |
| Wells, G | 1 |
| Carrier, M | 1 |
| Adam, SS | 1 |
| McDuffie, JR | 1 |
| Lachiewicz, PF | 1 |
| Ortel, TL | 2 |
| Williams, JW | 1 |
| Majeed, A | 3 |
| Hwang, HG | 2 |
| Connolly, SJ | 2 |
| Eikelboom, JW | 2 |
| Ezekowitz, MD | 2 |
| Wallentin, L | 2 |
| Brueckmann, M | 2 |
| Fraessdorf, M | 2 |
| Yusuf, S | 2 |
| Ghanima, W | 1 |
| Atar, D | 1 |
| Sandset, PM | 1 |
| Prandoni, P | 3 |
| Barbar, S | 1 |
| Milan, M | 1 |
| Vedovetto, V | 1 |
| Pesavento, R | 1 |
| Cove, CL | 1 |
| Hylek, EM | 1 |
| Rachidi, S | 1 |
| Aldin, ES | 1 |
| Greenberg, C | 1 |
| Sachs, B | 1 |
| Streiff, M | 1 |
| Zeidan, AM | 1 |
| Shapiro, S | 1 |
| Laffan, M | 1 |
| Dekkers, OM | 1 |
| Klok, FA | 1 |
| Verhamme, P | 1 |
| Bounameaux, H | 2 |
| Christiansen, AV | 1 |
| Le Maulf, F | 1 |
| Peter, N | 1 |
| Bloch, BV | 1 |
| Patel, V | 1 |
| Best, AJ | 1 |
| Giglio, AF | 1 |
| Basile, E | 1 |
| Santangeli, P | 1 |
| Di Biase, L | 1 |
| Trotta, F | 1 |
| Natale, A | 1 |
| Fontana, P | 1 |
| Antoniazzi, S | 1 |
| Berdaï, D | 1 |
| Conti, V | 1 |
| Clementi, E | 1 |
| Salvo, F | 1 |
| Thachil, J | 1 |
| Brieger, D | 1 |
| Granziera, S | 1 |
| Cohen, AT | 2 |
| Temraz, S | 1 |
| Taher, A | 1 |
| Holy, EW | 1 |
| Beer, JH | 2 |
| Yeh, CH | 1 |
| Gross, PL | 1 |
| Weitz, JI | 1 |
| Lévy, S | 1 |
| Kakkos, SK | 3 |
| Kirkilesis, GI | 3 |
| Tsolakis, IA | 3 |
| Chatterjee, S | 1 |
| Sardar, P | 1 |
| Giri, JS | 1 |
| Ghosh, J | 1 |
| Mukherjee, D | 1 |
| Kahale, L | 1 |
| Neumann, I | 1 |
| Labedi, N | 1 |
| Muti, P | 1 |
| Gómez-Outes, A | 2 |
| Terleira-Fernández, AI | 2 |
| Lecumberri, R | 1 |
| Suárez-Gea, ML | 2 |
| Vargas-Castrillón, E | 2 |
| Win, K | 1 |
| Rodgers, GM | 1 |
| Alotaibi, G | 1 |
| Alsaleh, K | 1 |
| Wu, C | 1 |
| Mcmurtry, MS | 1 |
| Amin, A | 1 |
| Jing, Y | 1 |
| Trocio, J | 1 |
| Lin, J | 1 |
| Lingohr-Smith, M | 1 |
| Graham, J | 1 |
| Akwaa, F | 1 |
| Kyrle, PA | 1 |
| Binder, K | 1 |
| Eichinger, S | 1 |
| Függer, R | 1 |
| Gollackner, B | 1 |
| Hiesmayr, JM | 1 |
| Huber, K | 1 |
| Lang, W | 1 |
| Perger, P | 1 |
| Quehenberger, P | 1 |
| Roithinger, FX | 1 |
| Schmaldienst, S | 1 |
| Weltermann, A | 1 |
| Domanovits, H | 1 |
| Sciascia, S | 1 |
| Hunt, BJ | 1 |
| Hifumi, T | 1 |
| Takada, H | 1 |
| Kiriu, N | 1 |
| Plitt, A | 1 |
| Giugliano, RP | 1 |
| Messori, A | 2 |
| Fadda, V | 2 |
| Maratea, D | 2 |
| Trippoli, S | 2 |
| Marinai, C | 1 |
| Ulrich, LR | 1 |
| Mergenthal, K | 1 |
| Petersen, JJ | 1 |
| Roehl, I | 1 |
| Rauck, S | 1 |
| Kemperdick, B | 1 |
| Schulz-Rothe, S | 1 |
| Berghold, A | 1 |
| Siebenhofer, A | 1 |
| Cui, J | 1 |
| Wu, B | 1 |
| Liu, C | 1 |
| Li, Z | 1 |
| Baber, U | 1 |
| Mastoris, I | 1 |
| Mehran, R | 1 |
| Douketis, J | 3 |
| Bell, AD | 3 |
| Eikelboom, J | 3 |
| Liew, A | 3 |
| Hajhosseiny, R | 1 |
| Sabir, I | 1 |
| Pontillo, D | 1 |
| Patruno, N | 1 |
| Sukovatykh, BS | 1 |
| Belikov, LN | 1 |
| Savchuk, OF | 1 |
| Sukovatykh, MB | 1 |
| Spanos, K | 1 |
| Giannoukas, AD | 1 |
| Arepally, GM | 1 |
| Trusler, M | 1 |
| Harel, Z | 1 |
| Sood, MM | 1 |
| Perl, J | 1 |
| Dias, JD | 1 |
| Norem, K | 1 |
| Doorneweerd, DD | 1 |
| Thurer, RL | 1 |
| Popovsky, MA | 1 |
| Omert, LA | 1 |
| Hurst, KV | 1 |
| Lee, R | 1 |
| Milosevic, I | 1 |
| Handa, A | 1 |
| Walti, C | 1 |
| Bächli, E | 1 |
| Tagarakis, GI | 1 |
| Karangelis, D | 1 |
| Daskalopoulos, ME | 1 |
| Tsilimingas, NB | 1 |
| Dahl, OE | 6 |
| Morris, TA | 1 |
| Michota, F | 1 |
| Oliver, M | 1 |
| Huo, MH | 1 |
| Kurth, AA | 2 |
| Hantel, S | 2 |
| Hermansson, K | 1 |
| Schnee, JM | 1 |
| Friedman, RJ | 3 |
| Lereun, C | 1 |
| Wells, P | 1 |
| Diamantopoulos, A | 1 |
| Rasul, F | 1 |
| Lees, M | 1 |
| Sengupta, N | 1 |
| Samama, CM | 1 |
| Streif, W | 1 |
| Douketis, JD | 1 |
| Gums, JG | 1 |
| Fisher, WD | 1 |
| Nutescu, E | 1 |
| Dumont, B | 1 |
| Faille, D | 1 |
| Ajzenberg, N | 1 |
| Welzel, D | 1 |
| Hull, R | 1 |
| Fareed, J | 1 |
| Keltai, M | 1 |
| Keltai, K | 1 |
| Asmis, LM | 1 |
| Eerenberg, ES | 1 |
| van Es, J | 1 |
| Sijpkens, MK | 1 |
| Büller, HR | 1 |
| Kamphuisen, PW | 1 |
| Augoustides, JG | 1 |
| Rosencher, N | 1 |
| Noack, H | 2 |
| Clemens, A | 2 |
| Migliaccio-Walle, K | 1 |
| Rublee, D | 2 |
| Simon, TA | 2 |
| Mahan, C | 1 |
| Cohen, A | 1 |
| Drost, P | 1 |
| Marchant, N | 1 |
| Mitchell, S | 1 |
| Orme, M | 1 |
| Sutton, A | 1 |
| Khemasuwan, D | 1 |
| Suramaethakul, N | 1 |
| Nieto, JA | 1 |
| Espada, NG | 1 |
| Merino, RG | 1 |
| González, TC | 1 |
| Tripodi, A | 1 |
| Palareti, G | 1 |
| Duh, PD | 1 |
| Leuckx, PS | 1 |
| Warnez, PM | 1 |
| McCullagh, L | 1 |
| Barry, M | 1 |
| Feuring, M | 1 |
| Huo, M | 1 |
| Harenberg, J | 1 |
| Marx, S | 1 |
| Marder, VJ | 1 |
| Schulze, A | 1 |
| Wehling, M | 1 |
| Weiss, C | 1 |
| Kreutz, R | 1 |
| Llau, J | 1 |
| Norrving, B | 1 |
| Tafur, A | 1 |
| Wysokinski, WE | 1 |
| McBane, RD | 1 |
| Aalbers, J | 1 |
| Blanco-Molina, A | 1 |
| Mahan, CE | 1 |
| Kaatz, S | 1 |
| Boehlen, F | 1 |
| de Moerloose, P | 1 |
| Shamoun, FE | 1 |
| Martin, EN | 1 |
| Money, SR | 1 |
| Perez, A | 1 |
| Eraso, LH | 1 |
| Merli, GJ | 1 |
| Gómez Arrayas, I | 1 |
| Suárez Fernández, C | 1 |
| Gómez Cerezo, JF | 1 |
| Betegón Nicolás, L | 1 |
| de Salas-Cansado, M | 1 |
| Rubio-Terrés, C | 1 |
| Samama, MM | 1 |
| Guinet, C | 1 |
| Le Flem, L | 1 |
| Ninin, E | 1 |
| Debue, JM | 1 |
| Rojas-Hernandez, CM | 1 |
| Garcia, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigation of Genetic Variations on Patients With Adverse Events While on Direct Oral Anticoagulants (DOACs)[NCT04580589] | 210 participants (Actual) | Observational | 2021-02-01 | Completed | |||
| Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism.[NCT00558259] | Phase 3 | 1,353 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembo[NCT00329238] | Phase 3 | 2,867 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis[NCT04981327] | Phase 3 | 1,300 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
| Prospective Observational Study of the Direct Oral Anticoagulants Periprocedural Management[NCT03182218] | 1,100 participants (Actual) | Observational | 2015-02-28 | Completed | |||
| A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial Treatm[NCT00680186] | Phase 3 | 2,589 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria[NCT00262600] | Phase 3 | 18,113 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate 150 mg Twice Daily Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (VTE), Following In[NCT00291330] | Phase 3 | 2,564 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| The Prevalence of Post-Thrombotic Syndrome in Deep-Vein Thrombosis (DVT) Patients Treated With Dabigatran- a Cross-Sectional Assessment of RE-COVER Study Patients[NCT03050138] | 351 participants (Actual) | Observational | 2016-04-30 | Completed | |||
| Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial Fibrillation: a Randomized, Multi-center, Parallel-group Trial (PILOT)[NCT03433235] | Phase 2 | 68 participants (Actual) | Interventional | 2018-06-19 | Completed | ||
| Pharmacogenetic Algorithm of Response to Warfarin During Initial Anticoagulation in Chinese Elderly Patients[NCT02211326] | 660 participants (Actual) | Interventional | 2014-09-01 | Completed | |||
| A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Comp[NCT00657150] | Phase 3 | 2,055 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| EXercise Training for the Prevention of Cancer Thrombosis (EXPECT) Pilot Trial[NCT01853202] | 40 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| Prospective Study of the Assessment of the Dental Protocol for Tooth Extraction in Patients With Atrial Fibrillation in Continuous Use of New Oral Anticoagulants: A Pilot Study[NCT03181386] | Phase 3 | 60 participants (Actual) | Interventional | 2017-05-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cardiovascular events that occurred during the treatment period + 3 days were summarised by treatment groups. (NCT00558259)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Dabigatran | 3 |
| Placebo | 2 |
Number of participants with centrally confirmed symptomatic pulmonary embolism (PE) events during the intended treatment period were described. (NCT00558259)
Timeframe: 6 months
| Intervention | Participants (Number) |
|---|---|
| Dabigatran | 1 |
| Placebo | 14 |
Number of the participants with centrally confirmed symptomatic recurrent deep venous thrombotic (DVT) events during the intended treatment period were described. (NCT00558259)
Timeframe: 6 months
| Intervention | Participants (Number) |
|---|---|
| Dabigatran | 2 |
| Placebo | 23 |
Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event. (NCT00558259)
Timeframe: 6 months
| Intervention | Participants (Number) |
|---|---|
| Dabigatran | 3 |
| Placebo | 35 |
Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event. (NCT00558259)
Timeframe: 6 months
| Intervention | Participants (Number) |
|---|---|
| Dabigatran | 3 |
| Placebo | 37 |
Number of participants with centrally confirmed unexplained deaths during the intended treatment period were described. (NCT00558259)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Dabigatran | 0 |
| Placebo | 2 |
"Major bleeding events (MBE) had to fulfil at least 1 of the following criteria:~Fatal bleeding~Associated with a fall in haemoglobin of ≥2 g/dL~Led to the transfusion of ≥2 units packed cells or whole blood~Occurred in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal~Other clinically relevant bleeding was defined as overt bleeding not meeting the criteria for an MBE but associated with medical intervention, unscheduled contact with a physician, (temporary) cessation of study treatment, or associated with discomfort such as pain, or impairment of activities of daily life.~Examples of these bleedings were:~Bleeding that compromised haemodynamics~Bleeding that led to hospitalisation~Trivial bleeding events were defined as all other bleeding events that did not fulfil the criteria of MBEs or CRBEs.~All bleeding events include MBEs, CRBEs, and trivial bleeding events." (NCT00558259)
Timeframe: 6 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| MBE | MBE or CRBE | All Bleeding | |
| Dabigatran | 2 | 36 | 72 |
| Placebo | 0 | 12 | 39 |
Number of participants with possible clinically significant abnormalities during the treatment period. (NCT00558259)
Timeframe: 6 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| AST increase (N=655, 629) | ALT increase (N=655, 629) | Alkaline phosphatase increase (N=658, 629) | Total bilirubin increase (N=658, 628) | |
| Dabigatran | 2 | 3 | 0 | 1 |
| Placebo | 2 | 5 | 0 | 1 |
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. (NCT00329238)
Timeframe: 18 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 36 | 1394 |
| Warfarin | 32 | 1394 |
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. (NCT00329238)
Timeframe: 36 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 42 | 1388 |
| Warfarin | 36 | 1390 |
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE. (NCT00329238)
Timeframe: 18 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 22 | 1408 |
| Warfarin | 17 | 1409 |
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE. (NCT00329238)
Timeframe: 36 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 26 | 1404 |
| Warfarin | 18 | 1408 |
Deaths of all causes at 18 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments. (NCT00329238)
Timeframe: 18 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 15 | 1415 |
| Warfarin | 16 | 1410 |
Deaths of all causes at 36 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments. (NCT00329238)
Timeframe: 36 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 17 | 1413 |
| Warfarin | 19 | 1407 |
Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way. (NCT00329238)
Timeframe: 18 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 1 | 1429 |
| Warfarin | 1 | 1425 |
Deaths related to VTE (i.e. fatal PE) at 36 Months. Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way. (NCT00329238)
Timeframe: 36 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 1 | 1429 |
| Warfarin | 1 | 1425 |
Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation. (NCT00329238)
Timeframe: 36 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 17 | 1413 |
| Warfarin | 13 | 1413 |
Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation. (NCT00329238)
Timeframe: 18 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 15 | 1415 |
| Warfarin | 12 | 1414 |
Patients with LFT (liver function tests) increases of possible clinical significance during treatment. Increases of possible clinical significance were defined as: ≥3 x ULN (AST, ALT), ≥2 x ULN (AP), and ≥2 mg/dL (total bilirubin). Only patients with a baseline value which was not of possible clinical significance (or without any baseline value) could have a PCSA (Possible clinically significant abnormality). (NCT00329238)
Timeframe: 18 months + 30 days follow up
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| ALT increase | AST increase | Alkaline phosphatase | Total bilirubin | |
| Dabigatran | 26 | 23 | 9 | 9 |
| Warfarin | 30 | 23 | 14 | 8 |
"MBE (major bleeding event) if it fulfilled at least one of the following criteria~Fatal bleeding~Symptomatic bleeding in a critical area or organ.~Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells.~Minor bleeding event was any bleeding that did not fulfil any of the criteria for MBEs~CRBE (clinically relevant bleeding event) if it is a minor bleeding events which fulfilled at least one of the following criteria~Spontaneous skin haematoma ≥25 cm2~Spontaneous nose bleed >5 min duration~Macroscopic haematuria, either spontaneous or, if associated with an intervention, lasting >24 h~Spontaneous rectal bleeding~Gingival bleeding >5 min~Bleeding leading to hospitalisation or requiring surgical treatment~Bleeding leading to a transfusion of <2 units of whole blood or red cells~Any other bleeding event considered clinically relevant by the investigator" (NCT00329238)
Timeframe: first intake of study drug until 6 days following last intake of study drug
| Intervention | participants (Number) | ||
|---|---|---|---|
| patients with MBE | patients with MBE and /or CRBE | patients with any bleeding event | |
| Dabigatran | 13 | 80 | 277 |
| Warfarin | 25 | 145 | 373 |
All suspected ACS occurring during the trial were to be recorded on the CRF and were to be centrally adjudicated by an independent ACS/AC in a treatment-blinded manner. (NCT00329238)
Timeframe: day of first study drug intake until last day of study drug intake; from the day after last intake of study drug until trial termination
| Intervention | participants (Number) | |
|---|---|---|
| During intake of study drug, N=1430 , N=1415 | After stopping study drug, N=1426, N=1400 | |
| Dabigatran | 12 | 1 |
| Warfarin | 2 | 5 |
Symptomatic pulmonary embolism (PE) at 18 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography. (NCT00329238)
Timeframe: 18 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 8 | 1422 |
| Warfarin | 5 | 1421 |
Symptomatic pulmonary embolism (PE) at 36 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography. (NCT00329238)
Timeframe: 36 months
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with event | Number of participants with no event | |
| Dabigatran | 10 | 1420 |
| Warfarin | 5 | 1421 |
Frequency of patients with possible clinically significant abnormalities. (NCT00680186)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase | AST decrease | ALT increase | ALT decrease | Bilirubin increase | Bilirubin decrease | |
| Dabigatran 150 mg | 29 | 0 | 31 | 0 | 8 | 0 |
| Warfarin | 27 | 0 | 40 | 0 | 6 | 0 |
Any deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 25 | 29 |
| Warfarin | 25 | 26 |
VTE - related deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. Hazard ratios and 95% CI were not calculated because of insufficient number of events. (NCT00680186)
Timeframe: From randomisation to 6 months (up to day 180) and to end of ptp (planned to be up to day 224)
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 3 | 3 |
| Warfarin | 0 | 0 |
Any ACS occurring during the conduct of the study (centrally adjudicated as definite). Patients having a centrally adjudicated definite ACS during intake of study drug and after stopping study drug, according to treatment group. ACS assessments pre-specified in the protocol without adjudication. Prior to database lock, the steering committee asked to have ACS events adjudicated by an independent committee. After database lock, the committee was provided with source documentation that was blinded to the patient's treatment assignment. ACS results presented are based on adjudication findings. (NCT00680186)
Timeframe: From first intake of study drug to last contact date
| Intervention | participants (Number) | |
|---|---|---|
| During intake of study drug | After stopping study drug | |
| Dabigatran 150 mg | 3 | 2 |
| Warfarin | 0 | 1 |
"Major bleeding events (MBE) are defined as~Fatal bleeding~Symptomatic bleeding in a critical area or organ~Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells~Clinically-relevant bleeding events (CRBE) are defined as~spontaneous skin hematoma >=25 cm²~wound hematoma >=100 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding~gingival bleeding >5 min~leading to hospitalisation and / or requiring surgical treatment~leading to a transfusion of <2 units of whole blood or red cells~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00680186)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout
| Intervention | participants (Number) | ||
|---|---|---|---|
| MBE | MBE and/or CRBE | Any bleeding event | |
| Dabigatran 150 mg | 15 | 64 | 200 |
| Warfarin | 22 | 102 | 285 |
Symptomatic DVT which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 25 | 28 |
| Warfarin | 17 | 17 |
Symptomatic fatal and non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 8 | 10 |
| Warfarin | 13 | 15 |
Symptomatic non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 7 | 9 |
| Warfarin | 13 | 15 |
All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 30 | 34 |
| Warfarin | 28 | 30 |
VTE or any death which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 51 | 57 |
| Warfarin | 48 | 51 |
Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN (NCT00262600)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Dabigatran 110 mg | 11 |
| Dabigatran 150 mg | 14 |
| Warfarin | 21 |
Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 1.54 |
| Dabigatran 150 mg | 1.11 |
| Warfarin | 1.71 |
Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.85 |
| Dabigatran 150 mg | 4.32 |
| Warfarin | 5.20 |
Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.26 |
| Dabigatran 150 mg | 3.68 |
| Warfarin | 4.35 |
"Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25~Major bleeds are adjudicated, whereas minor bleeds are investigator reported." (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) | |
|---|---|---|
| Major bleeds | Minor bleeds | |
| Dabigatran 110 mg | 2.99 | 13.16 |
| Dabigatran 150 mg | 3.55 | 14.85 |
| Warfarin | 3.81 | 16.37 |
Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH) (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage)] (Number) | |
|---|---|---|
| intracerebral hemorrhage | intracranial hemorrhage (ICH) | |
| Dabigatran 110 mg | 0.12 | 0.23 |
| Dabigatran 150 mg | 0.10 | 0.32 |
| Warfarin | 0.38 | 0.76 |
Frequency of patients with possible clinically significant abnormalities. (NCT00291330)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout (washout time can be reduced until 0 day if the patient takes an other anti-coagulant therapy on and after last intake of active study drug)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase | AST decrease | ALT increase | ALT decrease | Bilirubin increase | Bilirubin decrease | |
| Dabigatran 150 mg | 21 | 0 | 26 | 0 | 7 | 0 |
| Warfarin | 22 | 0 | 38 | 0 | 13 | 0 |
Any deaths which occured from randomisation to end of post treatment period. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 21 | 25 |
| Warfarin | 21 | 25 |
"VTE - related deaths which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 1 | 1 |
| Warfarin | 3 | 3 |
"Any ACS occurring during the conduct of the study (centrally adjudicated as definite).~Counts of patients having a centrally adjudicated definite ACS during intake of active study drug, after stopping active study drug and before or without intake of active study drug, according to treatment group.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: From first intake of study drug to end of study conduct
| Intervention | participants (Number) | ||
|---|---|---|---|
| During intake of active study drug | After stopping active study drug | Before/without intake of active study drug | |
| Dabigatran 150 mg | 5 | 4 | 2 |
| Warfarin | 3 | 2 | 0 |
"Major bleeding events (MBE) were defined as~Fatal bleeding~Symptomatic bleeding in a critical area or organ~Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells~Clinically-relevant bleeding events (CRBE) was defined as~spontaneous skin hematoma >=25 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding (more than spotting on toilet paper)~gingival bleeding >5 min~leading to hospitalisation and / or requiring surgical treatment~leading to a transfusion of <2 units of whole blood or red cells~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00291330)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout (washout time can be reduced until 0 day if the patient takes an other anti-coagulant therapy on and after last intake of active study drug)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding events | MBE and/or CRBE | Any bleeding events | |
| Dabigatran 150 mg | 20 | 71 | 207 |
| Warfarin | 24 | 111 | 280 |
"Symptomatic DVT which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 16 | 17 |
| Warfarin | 18 | 22 |
"Symptomatic non-fatal PE which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 13 | 16 |
| Warfarin | 7 | 8 |
All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)
| Intervention | Participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 30 | 34 |
| Warfarin | 27 | 32 |
"VTE or any death which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | Participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 48 | 55 |
| Warfarin | 44 | 53 |
All cause death, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 0 |
| Enoxaparin | 1 |
Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 18 |
| Enoxaparin | 33 |
Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 17 |
| Enoxaparin | 31 |
Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 1 |
| Enoxaparin | 2 |
Symptomatic Deep Vein Thrombosis, confirmed by venous duplex, ultrasound, venography or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 0 |
| Enoxaparin | 4 |
Total Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 60 |
| Enoxaparin | 67 |
"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).~All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients." (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 61 |
| Enoxaparin | 69 |
Volume of blood loss for treated and operated patients during surgery. (NCT00657150)
Timeframe: Day 1
| Intervention | mL (Mean) |
|---|---|
| Dabigatran 220mg | 404.9 |
| Enoxaparin | 411.0 |
Number of treated and operated patients with required blood transfusion on day of surgery. (NCT00657150)
Timeframe: Day 1
| Intervention | participants (Number) | |
|---|---|---|
| Transfusions required | Missing | |
| Dabigatran 220mg | 246 | 4 |
| Enoxaparin | 237 | 7 |
Frequency of patients with possible clinically significant abnormalities. (NCT00657150)
Timeframe: First administration to end of study
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase N=(964;962) | AST decrease N=(964;962) | ALT increase N=(966;962) | ALT decrease N=(966;962) | Bilirubin increase N=(966;962) | Bilirubin decrease N=(966;962) | |
| Dabigatran 220mg | 28 | 0 | 34 | 0 | 3 | 0 |
| Enoxaparin | 44 | 0 | 67 | 0 | 1 | 0 |
"Major bleeding events were defined as~fatal~clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected~clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected~symptomatic retroperitoneal, intracranial, intraocular or intraspinal~requiring treatment cessation~leading to re-operation~Clinically-relevant was defined as~spontaneous skin hematoma >=25 cm²~wound hematoma >=100 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding~gingival bleeding >5 min~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and minor bleeding events. Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Major bleeding events | Major and clinically relevant bleeding events | Any bleeding events | |
| Dabigatran 220mg | 14 | 37 | 98 |
| Enoxaparin | 9 | 29 | 83 |
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). (NCT00657150)
Timeframe: 3 months
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Total VTE and all-cause mortality | asymptomatic Deep Vein Thrombosis | symptomatic Deep Vein Thrombosis | Pulmonary Embolism | death | |
| Dabigatran 220mg | 2 | 0 | 1 | 1 | 0 |
| Enoxaparin | 4 | 1 | 0 | 2 | 1 |
78 reviews available for beta-alanine and Thromboembolism, Venous
| Article | Year |
|---|---|
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabiga | 2018 |
[Prophylaxis of venous thromboembolism in orthopedic surgery. Role of the new anticoagulants].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; bet | 2012 |
[New evidence in the secondary prevention of thromboembolic disease].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Biomarkers; Dabigatran; Fibrin Fibrinogen Degradation | 2012 |
[Recommendations on use of direct oral anticoagulants in the perioperative period].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran | 2012 |
Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2013 |
Venous thromboembolism management: where do novel anticoagulants fit?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor X; Heparin; Humans; Morpholines; Py | 2013 |
Thromboprophylaxis in patients with pelvic and acetabular fractures: A short review and recommendations.
Topics: Acetabulum; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Fondaparin | 2013 |
Novel oral anticoagulants: a review of new agents.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration S | 2013 |
New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration | 2013 |
New oral anticoagulants for the treatment of venous thromboembolism.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Ad | 2013 |
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Dabig | 2013 |
NOACs for thromboprophylaxis in medical patients.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administr | 2013 |
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; | 2013 |
Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
New oral anticoagulants--a review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2013 |
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; | 2014 |
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr | 2013 |
The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2013 |
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; | 2014 |
New oral anticoagulant agents - general features and outcomes in subsets of patients.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as To | 2014 |
Increased risk of myocardial infarction with dabigatran: fact or fiction?
Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2014 |
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
Topics: Acute Disease; Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials, P | 2014 |
Risk of major bleeding and the standard doses of dabigatran.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Ra | 2014 |
The newer direct oral anticoagulants: a practical guide.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2014 |
Anticoagulation: a GP primer on the new oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atri | 2014 |
Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabiga | 2014 |
Direct oral anticoagulants in the management of venous thromboembolism--evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabiga | 2014 |
Evolving use of new oral anticoagulants for treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy; Humans | 2014 |
Newer clinically available antithrombotics and their antidotes.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Elec | 2014 |
Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as To | 2014 |
Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigat | 2014 |
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabiga | 2014 |
Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; | 2014 |
Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Dabigat | 2014 |
The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pulmonary Em | 2014 |
Target-specific oral anticoagulants: practice issues for the clinician.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2014 |
Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu | 2015 |
A systematic review and adjusted indirect comparison of oral anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Mor | 2014 |
Balancing ischaemia and bleeding risks with novel oral anticoagulants.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; | 2014 |
Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; | 2014 |
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biomedical Research; Dabigatran; | 2014 |
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor | 2015 |
Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Rena | 2015 |
[Direct acting oral anticoagulants in venous thromboembolism].
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; | 2015 |
Dabigatran: the anticoagulant we have long expected?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Venous Throm | 2010 |
New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.
Topics: Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Fondaparinux; Humans; Morpholi | 2010 |
Intracerebral hemorrhage: Pick your poison.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Chronic Disease; Dabigatran; Huma | 2010 |
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhib | 2011 |
New anticoagulants: pharmacology and clinical studies.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2011 |
Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children.
Topics: Adolescent; Anticoagulants; Arginine; Benzimidazoles; beta-Alanine; Child; Child, Preschool; Dabigat | 2011 |
Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Co | 2011 |
New oral anticoagulants and outpatient prophylaxis of venous thromboembolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; bet | 2011 |
Characteristics of novel anticoagulants and potential economic implications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Cost Savings; Dabigatran; Health Care Costs; Humans; M | 2011 |
A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Orthopedic Procedures; Ri | 2011 |
[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tr | 2011 |
Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Evidence-Based | 2011 |
Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; | 2011 |
[The new Anticoagulants - Relevant Facts for the GP].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availab | 2011 |
Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Clini | 2011 |
Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.
Topics: Anesthesia, Conduction; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemistry | 2011 |
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; | 2012 |
Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controll | 2011 |
New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders.
Topics: Administration, Oral; Animals; Antithrombins; Arterial Occlusive Diseases; Benzimidazoles; beta-Alan | 2012 |
Improving prevention and treatment of venous thromboembolism: clinical trial results.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Economics, Pharm | 2012 |
The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.
Topics: Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta | 2012 |
Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; b | 2012 |
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinica | 2012 |
Long-term benefits of preventing venous thromboembolic events.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Follo | 2012 |
[Pharmacological sheet. Dabigatran, oral administration (Pradaxa)].
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic Agent | 2012 |
Treatment of venous thromboembolism with dabigatran.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Rivaro | 2012 |
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2012 |
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, R | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2012 |
Performance of new anticoagulants for thromboprophylaxis in patients undergoing hip and knee replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; bet | 2012 |
The novel anticoagulants: the surgeons' prospective.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Tr | 2013 |
Implications of new anticoagulants in primary practice.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthr | 2013 |
The novel oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; | 2013 |
6 trials available for beta-alanine and Thromboembolism, Venous
| Article | Year |
|---|---|
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; bet | 2010 |
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimida | 2011 |
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazol | 2012 |
51 other studies available for beta-alanine and Thromboembolism, Venous
| Article | Year |
|---|---|
Extended treatment of venous thromboembolism.
Topics: Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrinolytic Agents; Humans; Male; Pyrazoles; Pyri | 2013 |
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2013 |
DRESS syndrome induced by acenocoumarol with tolerance to warfarin and dabigatran: a case report.
Topics: Acenocoumarol; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Eru | 2013 |
[New oral anticoagulants in the treatment of venous thromboembolic disease].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholi | 2013 |
Venous thromboembolism: prophylactic and therapeutic practice guideline.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Chemoprevention; Dabigatran; Disease Management; Dose- | 2013 |
Conventional and new oral anticoagulants in the treatment of chest disease and its complications.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analy | 2013 |
[Venous thromboembolism. Currently it is worthwhile to use anticoagulants longer].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Long-Term Care; Morpholines; Pyraz | 2013 |
Randomised controlled trial: extended-duration dabigatran is non-inferior to warfarin and more effective than placebo for symptomatic VTE.
Topics: Benzimidazoles; beta-Alanine; Female; Humans; Male; Venous Thromboembolism; Warfarin | 2014 |
Extended anticoagulation in venous thromboembolism.
Topics: Benzimidazoles; beta-Alanine; Female; Humans; Male; Venous Thromboembolism; Warfarin | 2013 |
Extended anticoagulation in venous thromboembolism.
Topics: Benzimidazoles; beta-Alanine; Female; Humans; Male; Venous Thromboembolism; Warfarin | 2013 |
Extended anticoagulation in venous thromboembolism.
Topics: Benzimidazoles; beta-Alanine; Female; Humans; Male; Venous Thromboembolism; Warfarin | 2013 |
Extended anticoagulation in venous thromboembolism.
Topics: Benzimidazoles; beta-Alanine; Female; Humans; Male; Venous Thromboembolism; Warfarin | 2013 |
[New oral anticoagulant agents: the quandary of anticoagulation in the elderly].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug | 2013 |
New oral anticoagulants: their role and future.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2013 |
Direct oral anticoagulants for acute venous thromboembolism: closing the circle?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; | 2014 |
Thromboprophylaxis with dabigatran leads to an increased incidence of wound leakage and an increased length of stay after total joint replacement.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replace | 2014 |
Evidence suggests dabigatran is an effective and safe treatment for patients with VTE requiring early parenteral therapy.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Venou | 2014 |
New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Antithrombins; Benzimidazole | 2014 |
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fees, Pharmaceutical; Health Expenditures; | 2014 |
Dabigatran: patient management in specific clinical settings.
Topics: Antithrombins; Arthroplasty, Replacement; Austria; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrh | 2014 |
New oral anticoagulants in the management of venous thromboembolism: a major advance?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; | 2014 |
Letter by Hifumi et al regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Venous Thromboe | 2014 |
Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Venous Thromboe | 2014 |
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2014 |
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2014 |
Pitfalls of the interpretation of myocardial infarction data in patients on dabigatran treatment.
Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Humans; M | 2015 |
[Advantages and disadvantages of warfarin and pradaxa therapy for venous thromboembolism].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Dose-Response Relations | 2014 |
Response to 'Re: Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trial
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; | 2015 |
Re: 'Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; | 2015 |
Response.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Family Practice; Humans; Morpholines; Pyrazoles; Pyrid | 2015 |
Well-managed warfarin is superior to NOACs.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Family Practice; Humans; Morpholines; Pyrazoles; Pyrid | 2015 |
Re: 'Re. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-analysis of Phase III Trials'.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; | 2015 |
Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants.
Topics: Adolescent; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhib | 2015 |
Re: 'Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'- Key Learning Points fo
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; | 2015 |
Warfarin or not.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Pulmonary Embolism; Ve | 2010 |
New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigat | 2011 |
An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole | 2011 |
Place of dabigatran in contemporary pharmacotherapy.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat | 2011 |
[New anticoagulants in the prevention and treatment of venous thromboembolism].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials a | 2011 |
New anticoagulants: moving on from scientific results to clinical implementation.
Topics: Acute Coronary Syndrome; Anticoagulants; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzim | 2011 |
["Xa-tra-xa": opportunities and open questions about new anticoagulants].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Human | 2011 |
Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis | 2012 |
Prescribing trends for dabigatran etexilate in primary care.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabig | 2012 |
Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; | 2012 |
Dabigatran emerges as safe and effective warfarin alternative. The recently approved drug is more expensive, but appears to be more predictable.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug I | 2011 |
Periprocedural anticoagulant management.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Restenosis; Dabigatran; Heart | 2012 |
New ESC guidelines on atrial fibrillation accept reality of next generation of anti-coagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat | 2012 |
[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes].
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2012 |
[New anticoagulants: better knowledge, better prescriptions].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Eviden | 2012 |
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole | 2012 |
Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; | 2013 |